Skip to main content

Kura Oncology, Inc.

corporate_fare Company Profile

Kura Oncology, Inc.

KURA·NASDAQ·Life Sciences·CIK 0001422143

Kura Oncology, Inc. is a biopharmaceutical company focused on precision medicines for cancer treatment. Established in 2014, the company has evolved into a fully-integrated commercial-stage organization with a diversified pipeline of product candidates. Its pipeline comprises small molecules designed to target cancer signaling pathways. On November 13, 2025, the FDA approved Kura Oncology, Inc.'s new drug application for ziftomenib, marketed in the United States as KOMZIFTI™, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who lack satisfactory alternative treatment options. KOMZIFTI is the first and only menin inhibitor approved by the FDA for once-daily oral administration. Kura Oncology, Inc. is further evaluating ziftomenib across the AML treatment continuum, including in relapsed or refractory and newly diagnosed disease, and in patient subtypes representing up to 50% of AML cases. The clinical development program includes two registrational Phase 3 clinical trials of ziftomenib in combination with intensive and non-intensive chemotherapy in patients with newly diagnosed AML. Multiple clinical trials are also underway for ziftomenib in combination with standards of care in patients with relapsed or refractory and newly diagnosed AML with NPM1 and FLT3 co-mutations. Beyond AML, ziftomenib is being evaluated in combination with imatinib for gastrointestinal stromal tumors (GIST). The company is also exploring KO-7246, a next-generation menin inhibitor, for diabetes and cardiometabolic disorders, and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. Furthermore, Kura Oncology, Inc. is evaluating farnesyl transferase inhibitors (FTIs) in combination with various targeted therapies to address mechanisms of adaptive and innate resistance in solid tumor treatment.

Kura Oncology, Inc. (NASDAQ:KURA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for KURA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for KURA spans 4, 10-Q, 8-K.

Recent high-impact activity:

  • Kura CEO Troy Wilson Buys 200,000 Shares for $1.5 Million Open-Market
  • Kura's Q3 Revenue Misses by $10M Despite Narrower-Than-Expected Loss
  • Kura Q3 10-Q: $13.9M KOMZIFTI Quarter, $492.1M Cash, New $275M Oberland Facility
  • Kura Q3: KOMZIFTI Revenue Up 53% to $13.9M; Darlifarnib FDA Alignment
  • KOMZIFTI Revenue Jumps 53% to $13.9M as Kura Lands FDA Alignment on Second Program

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$67.48M
Net Income
-$278.67M
Diluted EPS
-$3.18
Op. Cash Flow
-$64.06M
Free Cash Flow
-$70.7M
Operating Income
-$303.63M
Cash & Equivalents
$149.1M
Total Debt
$9.71M
Debt / Equity
0.06×
Net Margin
-412.9%
Shares Outstanding
87.86M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-092567

Short Interest & Short Volume

7.86 days to cover

FINRA reported short interest of 12,640,858 shares in KURA as of the October 30, 2026 settlement, a 11.7% decrease from the prior period — about 7.9 days to cover at its recent average daily volume. On November 20, 2026, 48.5% of KURA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,640,858 shares as of October 30, 2026
Change vs prior period▼ 11.7%
Days to cover7.86 at avg daily volume of 1,609,207
Daily short volume (FINRA facilities)48.5% of 844,829 shares on November 20, 2026
5-day average short volume51.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for KURA, detected from its recent SEC filings · based on capital-structure filings through 2026-11-10.

ATM program1 shelf registration

New $150M ATM Program Registered · Replaces 2023 Shelf

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with K →
$6.94 +0.43% today
52-week range · as of 2026-11-17 $6.75 – $13.9
Market cap
$634.88M
Volume
1.8M (0.8× avg)
3-mo avg 2.3M
Live data · 2026-11-21 13:25 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed KURA - Latest Insights

KURA
Nov 16, 2026, 7:45 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $7.15
Real-time Price: $6.94 info
Change: -$0.210 (-3%) info
Market Cap: $634.882M info
KURA
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $7.29
Real-time Price: $6.94 info
Change: -$0.350 (-5%) info
Market Cap: $634.882M info
KURA
Nov 10, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.20
Real-time Price: $6.94 info
Change: -$0.260 (-4%) info
Market Cap: $634.882M info
KURA
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.45
Real-time Price: $6.94 info
Change: -$0.510 (-7%) info
Market Cap: $634.882M info
KURA
Nov 10, 2026, 4:02 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $7.45
Real-time Price: $6.94 info
Change: -$0.510 (-7%) info
Market Cap: $634.882M info
KURA
Sep 29, 2026, 5:15 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.70
Real-time Price: $6.94 info
Change: -$3.76 (-35%) info
Market Cap: $634.882M info
KURA
Sep 09, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.64
Real-time Price: $6.94 info
Change: -$5.70 (-45%) info
Market Cap: $634.882M info
KURA
Sep 09, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.64
Real-time Price: $6.94 info
Change: -$5.70 (-45%) info
Market Cap: $634.882M info
KURA
Aug 24, 2026, 5:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $12.32
Real-time Price: $6.94 info
Change: -$5.38 (-44%) info
Market Cap: $634.882M info
KURA
Aug 17, 2026, 4:45 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $11.76
Real-time Price: $6.94 info
Change: -$4.82 (-41%) info
Market Cap: $634.882M info
KURA
Aug 12, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.05
Real-time Price: $6.94 info
Change: -$3.11 (-31%) info
Market Cap: $634.882M info
KURA
Aug 12, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.12
Real-time Price: $6.94 info
Change: -$3.18 (-31%) info
Market Cap: $634.882M info
KURA
Jul 14, 2026, 7:02 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $11.45
Real-time Price: $6.94 info
Change: -$4.51 (-39%) info
Market Cap: $634.882M info
KURA
Jun 11, 2026, 8:02 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.83
Real-time Price: $6.94 info
Change: -$1.89 (-21%) info
Market Cap: $634.882M info
KURA
Jun 04, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.77
Real-time Price: $6.94 info
Change: -$1.83 (-21%) info
Market Cap: $634.882M info
KURA
Jun 03, 2026, 6:53 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $9.09
Real-time Price: $6.94 info
Change: -$2.15 (-24%) info
Market Cap: $634.882M info
KURA
May 26, 2026, 6:02 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $11.58
Real-time Price: $6.94 info
Change: -$4.64 (-40%) info
Market Cap: $634.882M info
KURA
May 12, 2026, 4:21 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $9.14
Real-time Price: $6.94 info
Change: -$2.20 (-24%) info
Market Cap: $634.882M info
KURA
May 12, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.36
Real-time Price: $6.94 info
Change: -$2.42 (-26%) info
Market Cap: $634.882M info
KURA
May 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.27
Real-time Price: $6.94 info
Change: -$2.33 (-25%) info
Market Cap: $634.882M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets